iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc. (NASDAQ: IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases.

iBio’s discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development. The company has also pursued its own preclinical pipeline while evaluating potential partnerships and licensing opportunities for its drug candidates and discovery technologies.

Historically, iBio was known for plant-based protein manufacturing and biologics development through its FastPharming technology, which was designed to produce proteins and antibodies using engineered plants. In more recent years, the company has shifted its emphasis toward artificial intelligence-enabled antibody discovery and therapeutic development. iBio is headquartered in the United States and serves the biopharmaceutical industry through its research, development and collaboration activities.

Key Stats

• Today's Range: $0.70 to $0.80
• 50-Day Range: $0.71 to $1.33
• 52-Week Range: $0.69 to $3.82
• Volume: 451,700 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $47.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

iBio Stock Analysis - MarketRank™

iBio scored higher than 54% of companies evaluated by MarketBeat, and ranked 493rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

iBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

iBio has a consensus price target of $6.00, representing about 721.9% upside from its current price of $0.73.

Amount of Analyst Coverage

iBio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for iBio are expected to decrease in the coming year, from ($0.39) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iBio is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iBio is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iBio has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.37% of the float of iBio has been sold short.

Short Interest Ratio / Days to Cover

iBio has a short interest ratio ("days to cover") of 7.15.

Change versus previous month

Short interest in iBio has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iBio does not currently pay a dividend.

Dividend Growth

iBio does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.90

News Sentiment

iBio has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for iBio this week, compared to 2 articles on an average week.

Search Interest

18 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

4 people have added iBio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.55% of the stock of iBio is held by insiders.

Percentage Held by Institutions

7.90% of the stock of iBio is held by institutions.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/13/2026
• 38th Annual Healthcare Conference: 12/01/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IBIO
• Previous Symbol: NYSEMKT:IBIO
• CIK: 1420720
• Web: ibioinc.com
• Phone: (302) 355-0650
• Fax: 302-356-1173
• Employees: 23
• Year Founded: N/A

Price Target and Rating

• Average Price Target for iBio: $6.00
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +720.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.04 million
• Net Margins: N/A
• Pretax Margin: -3,244.19%
• Return on Equity: -40.05%
• Return on Assets: -35.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.48
• Quick Ratio: 7.85

Sales & Book Value

• Annual Sales: $1.08 million
• Price / Sales: 43.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.12 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 64,307,000
• Free Float: 63,310,000
• Market Cap: $47.05 million
• Optionable: N/A
• Beta: 1.47